SummaryOtitis media is the most common
reason for children less than 5 years of age to visit a medical
practitioner. Whilst the disease rarely results in death, there is
significant associated morbidity. The most common complication is loss of
hearing at a critical stage of the development of speech, language and
cognitive abilities in children.The cause and pathogenesis of otitis
media is multifactorial. Among the contributing factors, the single most
important are viral and bacterial infections. Infection with respiratory
syncytial virus, influenza viruses, parainfluenza viruses, enteroviruses
and adenovirus are most commonly associated with acute and chronic otitis
media. Streptococcus pneumoniae, non-typeable Haemophilus
influenzae and Moraxella catarrhalis are the most commonly
isolated bacteria from the middle ears of children with otitis media.
Treatment of otitis media has largely relied on the administration of
antimicrobials and surgical intervention. However, attention has recently
focused on the development of a vaccine. For a vaccine to be effective
against bacterial otitis media, it must, at the very least, contain antigens
that induce a protective immune response in the middle ear against the three
most common infecting bacteria. Whilst over the past decade there has been
significant progress in the development of vaccines against invasive S.
pneumoniae disease, these vaccines are less efficacious for otitis
media. The search for candidate vaccine antigens for non-typeable H.
influenzae are well advanced whilst less progress has been made for
M. catarrhalis. No human studies have been conducted for non-typeable
H. influenzae or M. catarrhalis and the concept of a tribacterial
vaccine remains to be tested in animal models.
Only when vaccine antigens are determined and an understanding of the
immune responses induced in the middle ear by infection and immunization is
gained will the formulation of a tribacterial vaccine against otitis media
be possible.